| Literature DB >> 12142635 |
Takafumi Kuzuya1, Yozo Ogura, Yoko Motegi, Natsuko Moriyama, Toshitaka Nabeshima.
Abstract
The authors studied the effect of hematocrit, bilirubin, and alkaline phosphatase on microparticle enzyme immunoassay for tacrolimus II (MEIA II) using specimens of whole blood obtained from 33 patients undergoing cyclosporine treatment. Tacrolimus was added to these samples at a final concentration of 7.5 microg/L and 15 microg/L. Both coefficients of variation were over 20% (21% at 7.5 macrog/L of tacrolimus and 22% at 15 microg/L of tacrolimus). No correlation was found between bilirubin and tacrolimus concentrations or between alkaline phosphatase and tacrolimus concentrations. On the other hand, negative correlations were found between hematocrit values and tacrolimus concentrations (r2 = 0.47; P < 0.0001 at 7.5 microg/L tacrolimus, r2 = 0.54; P < 0.0001 at 15 microg/L tacrolimus). Negative correlations were also found between hematocrit and the tacrolimus concentration using normal human red blood cells diluted with physiological saline solution (r2 = 0.93; P < 0.0001 at 7.5 microg/L tacrolimus, r2 = 0.91; P < 0.0001 at 15 microg/L tacrolimus). The results showed that the hematocrit interferes with the MEIA II for tacrolimus, and the magnitude of the interference is clinically significant. Beyond the normal range of hematocrit values, caution should be exercised in interpreting results as one may need to compensate for the levels of tacrolimus.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12142635 DOI: 10.1097/00007691-200208000-00008
Source DB: PubMed Journal: Ther Drug Monit ISSN: 0163-4356 Impact factor: 3.681